Dennis Christensen

List of Publications by Year
in descending order

105 papers	4,828 citations	87723 38 h-index	106150 65 g-index
112 all docs	112 docs citations	112 times ranked	4646 citing authors

#	Article	IF	Citations
1	Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAFÂ®09b, in patients with metastatic melanoma. OncoImmunology, 2022, 11, 2023255.	2.1	18
2	A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease. International Journal of Molecular Sciences, 2022, 23, 1850.	1.8	4
3	Sublingual Boosting with A Novel Mucoadhesive Thermogelling Hydrogel Following Parenteral CAF01 Priming as A Strategy Against Chlamydia Trachomatis. Advanced Healthcare Materials, 2022, , 2102508.	3.9	7
4	Adjuvants, immunomodulators, and adaptogens. , 2022, , 223-280.		0
5	A gaps-and-needs analysis of vaccine R&D in Europe: Recommendations to improve the research infrastructure. Biologicals, 2022, 76, 15-23.	0.5	3
6	A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8+ T Cells with Ex Vivo Cytotoxic Capacities in HHDII/DR1 Transgenic Mice. Cancers, 2022, 14, 1970.	1.7	1
7	Monocytes Elicit a Neutrophil-Independent Th1/Th17 Response Upon Immunization With a Mincle-Dependent Glycolipid Adjuvant. Frontiers in Immunology, 2022, 13, 880474.	2.2	3
8	Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines. Cellular and Molecular Immunology, 2021, 18, 1197-1210.	4.8	14
9	Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAFÂ®01 or CDA/Î±GalCerMPEG. Vaccines, 2021, 9, 751.	2.1	6
10	Adsorption of protein antigen to the cationic liposome adjuvant CAFÂ®01 is required for induction of Th1 and Th17 responses but not for antibody induction. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 293-305.	2.0	9
11	Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice. EBioMedicine, 2021, 63, 103197.	2.7	31
12	Investigating Prime-Pull Vaccination through a Combination of Parenteral Vaccination and Intranasal Boosting. Vaccines, 2020, 8, 10.	2.1	9
13	Vaccine Adjuvants Differentially Affect Kinetics of Antibody and Germinal Center Responses. Frontiers in Immunology, 2020, 11, 579761.	2.2	36
14	CD4+ T Cells Induced by Tuberculosis Subunit Vaccine H1 Can Improve the HIV-1 Env Humoral Response by Intrastructural Help. Vaccines, 2020, 8, 604.	2.1	8
15	Applying Microfluidics for the Production of the Cationic Liposome-Based Vaccine Adjuvant CAF09b. Pharmaceutics, 2020, 12, 1237.	2.0	8
16	Pustulan Activates Chicken Bone Marrow-Derived Dendritic Cells In Vitro and Promotes Ex Vivo CD4+ T Cell Recall Response to Infectious Bronchitis Virus. Vaccines, 2020, 8, 226.	2.1	6
17	Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone. Frontiers in Immunology, 2020, 11, 803.	2.2	15
18	Cutting Edge: TNF Is Essential for Mycobacteria-Induced MINCLE Expression, Macrophage Activation, and Th17 Adjuvanticity. Journal of Immunology, 2020, 205, 323-328.	0.4	13

#	Article	IF	Citations
19	Translating the fabrication of protein-loaded poly(lactic-co-glycolic acid) nanoparticles from bench to scale-independent production using microfluidics. Drug Delivery and Translational Research, 2020, 10, 582-593.	3.0	50
20	Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunological Reviews, 2020, 296, 169-190.	2.8	56
21	Toll like-receptor agonist Pam3Cys modulates the immunogenicity of liposomes containing the tuberculosis vaccine candidate H56. Medical Microbiology and Immunology, 2020, 209, 163-176.	2.6	2
22	Injection Vaccines Formulated with Nucleotide, Liposomal or Mineral Oil Adjuvants Induce Distinct Differences in Immunogenicity in Rainbow Trout. Vaccines, 2020, 8, 103.	2.1	6
23	Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate. Veterinary Research, 2020, 51, 57.	1.1	4
24	Site-Specific DC Surface Signatures Influence CD4+ T Cell Co-stimulation and Lung-Homing. Frontiers in Immunology, 2019, 10, 1650.	2.2	12
25	Maternal Antibodies Inhibit Neonatal and Infant Responses to Vaccination by Shaping the Early-Life B Cell Repertoire within Germinal Centers. Cell Reports, 2019, 28, 1773-1784.e5.	2.9	63
26	Scale-Independent Microfluidic Production of Cationic Liposomal Adjuvants and Development of Enhanced Lymphatic Targeting Strategies. Molecular Pharmaceutics, 2019, 16, 4372-4386.	2.3	32
27	Design of Gadoteridol-Loaded Cationic Liposomal Adjuvant CAF01 for MRI of Lung Deposition of Intrapulmonary Administered Particles. Molecular Pharmaceutics, 2019, 16, 4725-4737.	2.3	5
28	Parenteral Vaccination With a Tuberculosis Subunit Vaccine in Presence of Retinoic Acid Provides Early but Transient Protection to M. Tuberculosis Infection. Frontiers in Immunology, 2019, 10, 934.	2.2	14
29	Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA. Journal of Controlled Release, 2019, 304, 65-74.	4.8	30
30	Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 140, 29-39.	2.0	19
31	Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization. Frontiers in Immunology, 2019, 10, 646.	2.2	14
32	Mucosal boosting of H56:CAF01 immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection. Mucosal Immunology, 2019, 12, 816-826.	2.7	43
33	A Liposome-Based Adjuvant Containing Two Delivery Systems with the Ability to Induce Mucosal Immunoglobulin A Following a Parenteral Immunization. ACS Nano, 2019, 13, 1116-1126.	7.3	22
34	Abstract B118: Development of a novel prostatic acid phosphatase-derived vaccine for the treatment of advanced prostate cancer. , 2019, , .		0
35	Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder. Vaccine, 2018, 36, 3331-3339.	1.7	33
36	Rational Design and In Vivo Characterization of Vaccine Adjuvants. ILAR Journal, 2018, 59, 309-322.	1.8	4

#	Article	IF	Citations
37	Immunocorrelates of CAF family adjuvants. Seminars in Immunology, 2018, 39, 4-13.	2.7	64
38	Dual-Isotope SPECT/CT Imaging of the Tuberculosis Subunit Vaccine H56/CAF01: Induction of Strong Systemic and Mucosal IgA and T-Cell Responses in Mice Upon Subcutaneous Prime and Intrapulmonary Boost Immunization. Frontiers in Immunology, 2018, 9, 2825.	2.2	23
39	Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01. Journal of Controlled Release, 2018, 291, 1-10.	4.8	19
40	Immune responses induced by nano-self-assembled lipid adjuvants based on a monomycoloyl glycerol analogue after vaccination with the Chlamydia trachomatis major outer membrane protein. Journal of Controlled Release, 2018, 285, 12-22.	4.8	17
41	Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan. Frontiers in Immunology, 2018, 9, 381.	2.2	43
42	Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C). Frontiers in Immunology, 2018, 9, 898.	2.2	18
43	Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses. Mucosal Immunology, 2017, 10, 260-270.	2.7	124
44	Adjuvants Based on Synthetic Mycobacterial Cord Factor Analogues: Biophysical Properties of Neat Glycolipids and Nanoself-Assemblies with DDA. Molecular Pharmaceutics, 2017, 14, 2294-2306.	2.3	11
45	Increased humoral immunity by DNA vaccination using an Î±-tocopherol-based adjuvant. Human Vaccines and Immunotherapeutics, 2017, 13, 1823-1830.	1.4	11
46	Systematic Investigation of the Role of Surfactant Composition and Choice of oil: Design of a Nanoemulsion-Based Adjuvant Inducing Concomitant Humoral and CD4+ T-Cell Responses. Pharmaceutical Research, 2017, 34, 1716-1727.	1.7	8
47	Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection. Npj Vaccines, 2017, 2, .	2.9	41
48	Alternatives to mineral oil adjuvants in vaccines against Aeromonas salmonicida subsp. salmonicida in rainbow trout offer reductions in adverse effects. Scientific Reports, 2017, 7, 5930.	1.6	11
49	TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development. Frontiers in Immunology, 2017, 8, 1203.	2.2	44
50	Development and Evaluation of CAF01. , 2017, , 333-345.		7
51	Seasonal Influenza Split Vaccines Confer Partial Cross-Protection against Heterologous Influenza Virus in Ferrets When Combined with the CAF01 Adjuvant. Frontiers in Immunology, 2017, 8, 1928.	2.2	21
52	Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes. PLoS ONE, 2017, 12, e0175707.	1.1	20
53	Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators. Pharmaceutics, 2016, 8, 7.	2.0	147
54	Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of Tuberculosis. PLoS ONE, 2016, 11, e0161217.	1.1	39

#	Article	IF	Citations
55	Nano-Self-Assemblies Based on Synthetic Analogues of Mycobacterial Monomycoloyl Glycerol and DDA: Supramolecular Structure and Adjuvant Efficacy. Molecular Pharmaceutics, 2016, 13, 2771-2781.	2.3	12
56	Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested Vaccine Adjuvants. Scientific Reports, 2016, 6, 39097.	1.6	53
57	The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8 + T-cell responses: The immunological consequences of the biodistribution profile. Journal of Controlled Release, 2016, 239, 107-117.	4.8	62
58	Vaccine adjuvants: Why and how. Human Vaccines and Immunotherapeutics, 2016, 12, 2709-2711.	1.4	56
59	Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization. Journal of Immunology, 2016, 197, 4413-4424.	0.4	79
60	Trehalose diester glycolipids are superior to the monoesters in binding to Mincle, activation of macrophages <i>inÂvitro</i> and adjuvant activity <i>inÂvivo</i>. Innate Immunity, 2016, 22, 405-418.	1.1	47
61	Intranasal vaccination with killed <i>Leishmania amazonensis</i> promastigotes antigen (LaAg) associated with CAF01 adjuvant induces partial protection in BALB/c mice challenged with <i>Leishmania (infantum) chagasi.</i>. Parasitology, 2015, 142, 1640-1646.	0.7	17
62	Characterization of the Antigen-Specific CD4+ T Cell Response Induced by Prime-Boost Strategies with CAF01 and CpG Adjuvants Administered by the Intranasal and Subcutaneous Routes. Frontiers in Immunology, 2015, 6, 430.	2.2	39
63	The Application of Liposomes as Vaccine Adjuvants. Advances in Delivery Science and Technology, 2015, , 77-94.	0.4	4
64	Influence of trehalose 6,6â€²-diester (TDX) chain length on the physicochemical and immunopotentiating properties of DDA/TDX liposomes. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 90, 80-89.	2.0	19
65	Peptide-specific T helper cells identified by MHC class II tetramers differentiate into several subtypes upon immunization with CAF01 adjuvanted H56 tuberculosis vaccine formulation. Vaccine, 2015, 33, 6823-6830.	1.7	15
66	Correlating liposomal adjuvant characteristics to in-vivo cell-mediated immunity using a novel <i>M</i> <i>ycobacterium tuberculosis</i> fusion protein: a multivariate analysis study. Journal of Pharmacy and Pharmacology, 2015, 67, 450-463.	1.2	8
67	A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4⁺ T-cell response. Nanomedicine, 2014, 9, 2625-2638.	1.7	13
68	Effect of Incorporating Cholesterol into DDA:TDB Liposomal Adjuvants on Bilayer Properties, Biodistribution, and Immune Responses. Molecular Pharmaceutics, 2014, 11, 197-207.	2.3	37
69	Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants. Journal of Pharmacy and Pharmacology, 2014, 66, 358-366.	1.2	36
70	Highâ€frequency vaccineâ€induced CD8⁺ T cells specific for an epitope naturally processed during infection with <i>Mycobacterium tuberculosis</i> do not confer protection. European Journal of Immunology, 2014, 44, 1699-1709.	1.6	42
71	The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4+ T-cells that protect against pulmonary infection in HLA-DR transgenic mice and guinea pigs. Vaccine, 2014, 32, 3580-3588.	1.7	25
72	Elucidating the mechanisms of protein antigen adsorption to the CAF/NAF liposomal vaccine adjuvant systems: Effect of charge, fluidity and antigen-to-lipid ratio. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 2001-2010.	1.4	35

#	Article	IF	Citations
73	Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant. Vaccine, 2014, 32, 3927-3935.	1.7	97
74	The Physical Stability of the Recombinant Tuberculosis Fusion Antigens H1 and H56. Journal of Pharmaceutical Sciences, 2013, 102, 3567-3578.	1.6	21
75	Designing CAF-adjuvanted dry powder vaccines: Spray drying preserves the adjuvant activity of CAF01. Journal of Controlled Release, 2013, 167, 256-264.	4.8	38
76	Protein Antigen Adsorption to the DDA/TDB Liposomal Adjuvant: Effect on Protein Structure, Stability, and Liposome Physicochemical Characteristics. Pharmaceutical Research, 2013, 30, 140-155.	1.7	43
77	The supramolecular structure is decisive for the immunostimulatory properties of synthetic analogues of a mycobacterial lipid in vitro. RSC Advances, 2013, 3, 20673-20683.	1.7	16
78	The Mincle-Activating Adjuvant TDB Induces MyD88-Dependent Th1 and Th17 Responses through IL-1R Signaling. PLoS ONE, 2013, 8, e53531.	1.1	130
79	Synchronization of Dendritic Cell Activation and Antigen Exposure Is Required for the Induction of Th1/Th17 Responses. Journal of Immunology, 2012, 188, 4828-4837.	0.4	78
80	Increased Immunogenicity and Protective Efficacy of Influenza M2e Fused to a Tetramerizing Protein. PLoS ONE, 2012, 7, e46395.	1.1	35
81	Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status. Expert Review of Vaccines, 2012, 11, 561-577.	2.0	34
82	A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog. Journal of Controlled Release, 2012, 160, 468-476.	4.8	101
83	Comparison of the Depot Effect and Immunogenicity of Liposomes Based on Dimethyldioctadecylammonium (DDA), 3Î²-[<i>N</i>-(<i>N</i>â€²,<i>N</i>â€²-Dimethylaminoethane)carbomyl] Cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium Propane (DOTAP): Prolonged Liposome Retention Mediates Stronger Th1 Responses. Molecular Pharmaceutics, 2011, 8, 153-161.	2.3	96
84	Cationic liposomes as vaccine adjuvants. Expert Review of Vaccines, 2011, 10, 513-521.	2.0	166
85	Liposomal vaccine delivery systems. Expert Opinion on Drug Delivery, 2011, 8, 505-519.	2.4	120
86	Immunity by formulation design: Induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. Journal of Controlled Release, 2011, 150, 307-317.	4.8	85
87	Microscopy imaging of liposomes: From coverslips to environmental SEM. International Journal of Pharmaceutics, 2011, 417, 138-150.	2.6	107
88	CAF01 Potentiates Immune Responses and Efficacy of an Inactivated Influenza Vaccine in Ferrets. PLoS ONE, 2011, 6, e22891.	1.1	29
89	CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. International Journal of Pharmaceutics, 2010, 390, 19-24.	2.6	54
90	Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. Journal of Controlled Release, 2010, 142, 180-186.	4.8	182

#	Article	IF	Citations
91	Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. Journal of Controlled Release, 2010, 145, 102-108.	4.8	152
92	Syringe Free Vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles Provides Strong and Prolonged Protection Against Tuberculosis. PLoS ONE, 2010, 5, e15043.	1.1	15
93	Protection against Chlamydia Promoted by a Subunit Vaccine (CTH1) Compared with a Primary Intranasal Infection in a Mouse Genital Challenge Model. PLoS ONE, 2010, 5, e10768.	1.1	54
94	Novel Generation Mycobacterial Adjuvant Based on Liposome-Encapsulated Monomycoloyl Glycerol from Mycobacterium bovis Bacillus Calmette-GuÃ©rin. Journal of Immunology, 2009, 183, 2294-2302.	0.4	39
95	Liposome-based cationic adjuvant formulations (CAF): Past, present, and future. Journal of Liposome Research, 2009, 19, 2-11.	1.5	105
96	A Liposome-Based Mycobacterial Vaccine Induces Potent Adult and Neonatal Multifunctional T Cells through the Exquisite Targeting of Dendritic Cells. PLoS ONE, 2009, 4, e5771.	1.1	91
97	Protein adsorption and displacement at lipid layers determined by total internal reflection fluorescence (TIRF). Journal of Liposome Research, 2009, 19, 99-104.	1.5	11
98	Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements. PLoS ONE, 2008, 3, e3116.	1.1	262
99	NIR transmission spectroscopy for rapid determination of lipid and lyoprotector content in liposomal vaccine adjuvant system CAF01. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 914-920.	2.0	19
100	Î±,Î±â€²-trehalose 6,6â€²-dibehenate in non-phospholipid-based liposomes enables direct interaction with trehalose, offering stability during freeze-drying. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 1365-1373.	1.4	36
101	Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 2120-2129.	1.4	79
102	The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology, 2007, 121, 216-226.	2.0	167
103	Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. Journal of Controlled Release, 2007, 119, 102-110.	4.8	52
104	Cationic liposomes as vaccine adjuvants. Expert Review of Vaccines, 2007, 6, 785-796.	2.0	126
105	Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6â€²-dibehenate)â€"A novel adjuvant inducing both strong CMI and antibody responses. Biochimica Et Biophysica Acta - Biomembranes, 2005, 1718, 22-31.	1.4	314